Apimeds Pharmaceuticals US, Inc. announced the closing of its initial public offering on May 12, 2025. The company issued 3,375,000 shares of common stock at a public offering price of $4.00 per share, generating gross proceeds of $13.5 million.
Following the deduction of underwriting discounts and other related expenses, Apimeds secured net cash proceeds of $11.90 million from the offering. The shares began trading on the NYSE American on May 9, 2025, under the symbol 'APUS'.
The company plans to utilize these net proceeds to fund a Phase III clinical trial for Apitox in knee osteoarthritis, initiate at least one non-registered corporate sponsorship study in multiple sclerosis, manufacture its product candidate, and address general working capital needs. This capital infusion is critical for advancing Apimeds' clinical development pipeline and operational expansion.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.